375 related articles for article (PubMed ID: 20230412)
21. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
[TBL] [Abstract][Full Text] [Related]
23. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin.
Mitsuguro M; Okamoto A; Shironouchi Y; Sano M; Miyata S; Neki R; Araki T; Hamamoto T; Yoshimatsu J; Miyata T
Int J Hematol; 2015 Feb; 101(2):119-25. PubMed ID: 25416968
[TBL] [Abstract][Full Text] [Related]
24. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
[TBL] [Abstract][Full Text] [Related]
25. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
[TBL] [Abstract][Full Text] [Related]
26. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
27. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
[TBL] [Abstract][Full Text] [Related]
28. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
29. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
[TBL] [Abstract][Full Text] [Related]
30. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
31. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
Belk KW; Laposata M; Craver C
J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
[TBL] [Abstract][Full Text] [Related]
32. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
33. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
Ip BK; Thomson AR; Moriarty HT
Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
[TBL] [Abstract][Full Text] [Related]
34. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
Eikelboom JW; Hirsh J
Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
[TBL] [Abstract][Full Text] [Related]
35. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin.
van Roessel S; Middeldorp S; Cheung YW; Zwinderman AH; de Pont AC
Neth J Med; 2014 Jul; 72(6):305-10. PubMed ID: 25319855
[TBL] [Abstract][Full Text] [Related]
38. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
[TBL] [Abstract][Full Text] [Related]
39. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
Korte W; Jovic R; Hollenstein M; Degiacomi P; Gautschi M; Ferrández A
Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
[TBL] [Abstract][Full Text] [Related]
40. In vivo age dependency of unfractionated heparin in infants and children.
Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
